Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT1ZAVI)

• DTT Name: Prostaglandin E2 receptor EP2 (PTGER2) DTT Info
• Gene Name: PTGER2

Molecule-Related Drug & Molecule List

6 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alprostadil	DMWH7NQ	Aorta coarctation		Approved	[1]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[2]
Iloprost	DMVPZBE	Pulmonary arterial hypertension	BB01.0	Approved	[3]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[4]
Omidenepag isopropyl	DMUX7Z8	Glaucoma/ocular hypertension	9C61	Approved	[5]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[6]

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[7]
CP-533536	DMZEJLB	Osteoporosis	FB83.0	Phase 2	[8]
Taprenepag	DM1TSHL	Glaucoma/ocular hypertension	9C61	Phase 2	[9]
PF-4418948	DMMETU8	Endometriosis	GA10	Phase 1	[2]
TPST-1495	DM3GSB2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[11]

16 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BUTAPROST	DMVYNJZ	Discovery agent	N.A.	Patented	[2]
PMID25772215-Compound-EP20082149552C9	DMVWF6I	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-EP2149552diaminopyrimidines	DM48YKE	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-US02014179750M1	DM7EKZ6	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-US02014179750M2	DMC50F3	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-US02014179750M3	DMJA1XC	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-US02014179750TG6-10-1	DMWD1FP	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-US02014179750TG6-129	DMRLZD2	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-US02014179750TG7-112-2	DMB87WZ	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-US02014179750TG7-170	DMORK8H	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-US02014179750TG7-74	DM9I4EV	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-US02014179750TG7-76	DMRTZC4	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-US02014179750TG8-15	DM8IL6Y	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-WO2012177618M4	DMD3CB4	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-WO2012177618M5	DMWUK9X	N. A.	N. A.	Patented	[2]
PMID25772215-Compound-WO2012177618M6	DMDCZVI	N. A.	N. A.	Patented	[2]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ONO-8815Ly	DM4CVEG	Miscarriage	JA00.0	Terminated	[12]

23 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
11-deoxy-PGE1	DM1ERJC	Discovery agent	N.A.	Investigative	[7]
17-phenyl-omega-trinor-PGE2	DM9OMI3	Discovery agent	N.A.	Investigative	[13]
19(R)-OH-PGE2	DMGUKCF	Discovery agent	N.A.	Investigative	[13]
3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid	DM8P26J	Discovery agent	N.A.	Investigative	[14]
3-(2-(4-methoxycinnamyl)phenyl)acrylic acid	DM61CHU	Discovery agent	N.A.	Investigative	[14]
3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid	DM9O5CH	Discovery agent	N.A.	Investigative	[14]
3-(2-cinnamylphenyl)acrylic acid	DM4XWME	Discovery agent	N.A.	Investigative	[14]
AH13205	DM2VEHG	Discovery agent	N.A.	Investigative	[7]
AH6809	DMKN3R9	Discovery agent	N.A.	Investigative	[15]
butaprost (free acid form)	DM5MZHP	Discovery agent	N.A.	Investigative	[11]
carbacyclin	DMMBQYE	Discovery agent	N.A.	Investigative	[15]
cicaprost	DM7ZJ4H	Discovery agent	N.A.	Investigative	[7]
isocarbacyclin	DMZR7W6	Discovery agent	N.A.	Investigative	[7]
M&B 28767	DMJQG82	Discovery agent	N.A.	Investigative	[13]
ONO-AE-248	DMA7VP5	Discovery agent	N.A.	Investigative	[16]
ONO-AE1-329	DMS3MZG	Discovery agent	N.A.	Investigative	[16]
PF-00212062	DMRHIMC	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
PGD2	DMYDW6J	Discovery agent	N.A.	Investigative	[11]
PMID20080612C1	DMV8ZFA	Discovery agent	N.A.	Investigative	[17]
R-65	DMSHMIK	Glaucoma/ocular hypertension	9C61	Investigative	[4]
TG4-155	DM862TI	Discovery agent	N.A.	Investigative	[18]
TG7-171	DM0OHL3	Discovery agent	N.A.	Investigative	[19]
U46619	DM13FX4	Discovery agent	N.A.	Investigative	[13]

References

• [1] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [2] Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
• [3] Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
• [5] Clinical pipeline report, company report or official report of Santen Pharmaceutical.
• [6] Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
• [7] Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
• [8] Pfizer. Product Development Pipeline. March 31 2009.
• [9] A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
• [10] Clinical pipeline report, company report or official report of Tempest Therapeutics.
• [11] Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51.
• [12] Prostaglandin E2 receptor type 2-selective agonist prevents the degeneration of articular cartilage in rabbit knees with traumatic instability. Arthritis Res Ther. 2011;13(5):R146.
• [13] Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
• [14] Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
• [15] The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
• [16] The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9.
• [17] Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2307-12.
• [18] Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3149-54.
• [19] Development of second generation EP2 antagonists with high selectivity. Eur J Med Chem. 2014 Jul 23;82:521-35.